prodchem
Aug 31, 2026
Drug development retrospectives presented around the ACS Fall Meeting offer more than historical accounts of individual programs. By examining how candidates move from scientific hypotheses to clinical testing, these reviews can reveal recurring lessons about target validation, molecular design, safety, manufacturing and the challenges of translating promising chemistry into medicines.
The pharmaceutical industry invests billions of dollars in discovering and developing new medicines.
Yet many candidates never reach patients.
Some fail during preclinical testing.
Others demonstrate promising early clinical results but disappoint in larger trials.
Some survive years of development only to be discontinued because of safety concerns, insufficient differentiation or commercial limitations.
These failures can be costly, but they also generate valuable knowledge.
Drug-development retrospectives provide a structured way to examine that knowledge.
A conventional drug-development story often focuses on the final outcome.
A successful candidate becomes a case study in innovation.
A failed candidate may simply disappear from the industry's attention.
Retrospectives offer a different approach.
They examine the complete development journey:
Target selection → Discovery → Lead optimization → Preclinical testing → Clinical trials → Regulatory strategy → Manufacturing → Commercialization
Looking across these stages can reveal where assumptions were correct, where they failed and where unexpected biological or technical problems emerged.
The American Chemical Society (ACS) brings together researchers working across chemistry, biology, materials science and related disciplines.
That makes its major scientific meetings particularly relevant to drug discovery.
The ACS Fall Meeting provides an environment where medicinal chemists, process chemists, computational researchers and pharmaceutical scientists can exchange ideas.
For drug-development retrospectives, this cross-disciplinary setting is especially valuable.
A clinical failure may originate from a biological problem, but it may also involve molecular properties, formulation, metabolism or manufacturing.
Understanding the complete story requires perspectives from multiple disciplines.
Many drug programs begin with a compelling hypothesis.
Researchers identify a target believed to contribute to disease.
The assumption is that changing that target will produce a therapeutic benefit.
But human biology is rarely as straightforward as laboratory models suggest.
A target can be:
Biologically relevant
Drugable
Associated with disease
Strongly validated in experimental systems
and still fail to produce sufficient clinical benefit.
Retrospectives can therefore help researchers distinguish between target validity and clinical druggability.
Even when a target is biologically attractive, designing a suitable molecule can be difficult.
Medicinal chemists must balance:
Potency
Selectivity
Solubility
Stability
Absorption
Distribution
Metabolism
Toxicity
Improving one property can worsen another.
A highly potent molecule may have poor pharmacokinetics.
A selective compound may not reach sufficient concentrations in the relevant tissue.
A molecule with excellent laboratory activity may become unstable during metabolism.
These trade-offs often determine whether a promising program survives.
A successful drug demonstrates that a particular development strategy worked.
A failed drug can reveal why a strategy did not work.
That information can be even more valuable.
For example, a failed candidate may show that:
The target was not sufficiently engaged
The biological response was too weak
The dose required was unsafe
The molecule could not reach the target tissue
Off-target activity created toxicity
The clinical endpoint was poorly selected
Retrospectives make these lessons easier to capture and transfer to future programs.
Medicinal chemistry relies heavily on understanding how structural changes affect biological activity.
Researchers systematically modify molecules and evaluate the consequences.
This produces structure-activity relationship, or SAR, data.
Over time, chemists learn which parts of a molecule control:
Potency
Selectivity
Solubility
Stability
Metabolic clearance
Retrospectives can demonstrate how seemingly small structural changes ultimately determine whether a candidate becomes viable.
Modern drug discovery increasingly combines experimental chemistry with computational methods.
Researchers can use computational tools to:
Predict molecular interactions
Explore chemical space
Identify promising compounds
Estimate physicochemical properties
Optimize binding
Model potential liabilities
Artificial intelligence has expanded these capabilities.
However, retrospectives can help demonstrate an important limitation:
Prediction is not validation.
Computationally attractive molecules still need experimental testing.
A candidate can perform exceptionally well in laboratory studies and still fail in humans.
This is particularly common in complex diseases.
Animal models may not fully reproduce human disease biology.
Biomarkers may not accurately predict patient outcomes.
The human immune system, metabolism and disease progression may differ substantially from experimental models.
Therefore, successful drug discovery requires a continuous feedback loop:
Laboratory evidence → Human data → Scientific reassessment → Candidate optimization
Retrospectives can show where that feedback loop succeeded or broke down.
Safety is another recurring theme in drug development.
A candidate may show efficacy but have an insufficient therapeutic window.
The problem may arise from:
Off-target binding
Reactive metabolites
Organ toxicity
Immune reactions
Drug-drug interactions
Retrospectives can help researchers understand whether these risks could have been detected earlier.
This is particularly valuable for improving preclinical screening strategies.
Clinical development requires identifying the dose that provides sufficient efficacy without unacceptable toxicity.
This is not always straightforward.
A candidate may require high exposure to achieve meaningful target engagement.
If that exposure approaches the safety limit, the program may have little room for optimization.
The result is a narrow therapeutic window.
Retrospective analysis can help researchers understand how pharmacokinetic and pharmacodynamic data should be integrated during dose selection.
Biomarkers can provide evidence that a drug is affecting its intended biological pathway.
Examples include:
Protein levels
Genetic signatures
Metabolites
Imaging measurements
Hormonal markers
A strong biomarker strategy can help answer an important question:
Is the drug failing because the target is wrong, or because the drug is not sufficiently engaging the target?
Without that information, companies may incorrectly abandon a valid biological mechanism—or continue investing in an ineffective one.
Drug discovery discussions sometimes focus heavily on biology and medicinal chemistry.
But a successful medicine must eventually be manufactured at scale.
Process chemistry therefore becomes critical.
A promising molecule may require:
Complex synthesis
Expensive reagents
Difficult purification
Hazardous intermediates
Low-yield reactions
Process chemists must redesign the route to make commercial production feasible.
This can involve:
Reducing synthetic steps
Improving reaction yields
Replacing hazardous solvents
Introducing catalytic reactions
Simplifying purification
The transition from laboratory synthesis to commercial manufacturing can fundamentally change the economics of a drug.
Environmental performance is increasingly becoming part of process development.
Pharmaceutical companies are evaluating:
Solvent consumption
Waste generation
Energy use
Water consumption
Carbon emissions
Material efficiency
A retrospection of a successful medicine can therefore reveal not only how the molecule was discovered, but how its manufacturing process evolved.
That information can help future developers design more sustainable processes from the beginning.
One of the most important lessons from modern drug-development retrospectives is that no single scientific discipline controls the entire process.
Successful programs require collaboration among:
Medicinal chemists
Biologists
Pharmacologists
Toxicologists
Clinical researchers
Computational scientists
Process chemists
Manufacturing engineers
Regulatory specialists
The handoff between these groups can create vulnerabilities.
Retrospectives help identify where communication gaps or incorrect assumptions affected development.
Many promising drug candidates originate in biotechnology companies and later move into larger pharmaceutical organizations.
An acquisition can provide access to:
Capital
Manufacturing infrastructure
Regulatory expertise
Clinical-development capabilities
Commercial resources
But integration can also change the strategic direction of a program.
A retrospective can reveal how ownership changes affected development decisions and resource allocation.
The value of a retrospective increases when its lessons remain relevant to current research.
A drug developed years ago may have used older technologies.
But the underlying challenges may still exist.
These include:
Target validation
Therapeutic-window optimization
Patient selection
Clinical endpoint design
Manufacturing scalability
Modern technologies can improve these processes, but they do not eliminate the underlying scientific uncertainty.
The pharmaceutical industry often faces a difficult problem.
Different companies can independently encounter similar development failures without knowing that another organization already experienced the same issue.
Publishing and discussing development histories can reduce this duplication.
For example, a retrospective may show that a particular target consistently produces a safety liability.
Future researchers can then incorporate that information into early-stage decision-making.
This transforms historical development data into a practical research asset.
Metabolic medicines provide a particularly useful example.
Programs targeting lipid metabolism, appetite regulation or glucose control have frequently encountered complex biological feedback mechanisms.
A candidate may improve one metabolic parameter while worsening another.
Retrospectives can help researchers understand these trade-offs.
They can also reveal why certain approaches were abandoned while others eventually succeeded.
Cancer drug development provides another strong example.
A molecule may be highly active against a cancer target but fail because tumors develop resistance.
This has encouraged combination strategies and biomarker-guided treatment.
Retrospectives can show how the understanding of resistance evolved during development.
Rare-disease programs face a different set of challenges.
Patient populations may be small.
Clinical endpoints may be difficult to establish.
Natural-history data can be limited.
Retrospectives can help explain how developers overcame these challenges through innovative trial designs, biomarkers or regulatory strategies.
The growing use of AI could make drug-development retrospectives even more useful.
Historical development data can potentially be analyzed to identify patterns across programs.
Researchers could examine relationships between:
Molecular structures
Targets
Toxicity signals
Clinical outcomes
Biomarkers
Patient characteristics
The objective would be to identify recurring predictors of success or failure.
Such approaches could help transform scattered historical knowledge into a more systematic development-learning system.
Not every failed program has the same explanation.
A molecule may fail because of its chemistry.
Another may fail because the target was wrong.
A third may fail because the clinical trial was poorly designed.
Therefore, retrospective analysis must avoid oversimplifying outcomes.
The correct question is not:
Why did this drug fail?
It is:
Which specific assumptions failed, at which stage, and what evidence demonstrated that failure?
That distinction makes retrospectives more useful.
There is also a direct financial incentive.
Clinical failures can cost pharmaceutical companies hundreds of millions or billions of dollars.
Reducing even a small percentage of avoidable failures could generate significant value.
Better historical learning can help companies make earlier decisions about whether to:
Continue development
Modify a molecule
Change an indication
Redesign a trial
Pursue combination therapy
Stop investing
The ability to stop weak programs earlier can be as valuable as accelerating successful ones.
The ultimate goal should not be simply documenting history.
Companies can convert retrospective findings into development playbooks.
For example:
Target validation checklist
Early safety-screening framework
Biomarker strategy
Clinical endpoint-selection framework
Manufacturing-readiness assessment
Go/no-go decision criteria
These tools can help embed historical lessons into future research programs.
ACS Fall Meeting drug-development retrospectives can provide several broad lessons:
A discontinued candidate can generate valuable scientific information.
Early assumptions should be tested against human evidence.
A strong target needs a molecule with the right properties.
Preclinical success does not guarantee patient benefit.
Commercial feasibility should not be left until the end of development.
Drug development is a chain of interconnected decisions.
Companies can use previous development outcomes to improve current programs.
Drug-development retrospectives associated with the ACS Fall Meeting offer an important opportunity for the pharmaceutical industry to learn from both success and failure.
The most valuable lessons often emerge not from the final approval of a medicine, but from the difficult decisions that came before it.
Why was a particular target selected?
How did medicinal chemists overcome molecular limitations?
Which safety signals emerged?
Why did a clinical trial succeed or fail?
How was the manufacturing process redesigned?
And when did the development team decide that the evidence was strong enough to continue—or weak enough to stop?
Answering these questions turns individual drug histories into industry-wide knowledge.
As pharmaceutical research becomes more expensive and scientifically complex, the ability to learn systematically from previous programs will become increasingly important.
The future of drug development will depend not only on discovering new molecules, targets and technologies.
It will also depend on the industry's ability to remember what worked, understand what failed and apply those lessons before repeating the same mistakes.
Featured Product
Found this useful?
Continue Reading
Japan's 15-year rare earth diversification campaign highlights the growing importance of critical mineral security. The strategy offers useful lessons for chemical traders, importers and industrial buyers managing concentrated supply chains.
The ACS lifetime membership pilot reflects a broader governance modernization effort within the professional chemistry community. The move could reshape how long-term engagement and membership value evolve across scientific organizations.
Atmospheric water generation systems can transfer indoor pollutants into condensation-derived drinking water, creating new questions for purity, treatment and procurement standards. The shift could increase demand for advanced water treatment solutions and stronger supplier specifications.
